Citigroup Maintains Buy on Zai Lab, Raises Price Target to $45
Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and raises the price target from $44 to $45.
Read original at benzingaStocks · News reference
Zai Lab Says FDA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3 Antibody-Drug Conjugate, For Treatment Of Neuroendocrine Carcinomas
- NECs are aggressive malignancies with poor prognoses and limited treatment options, representing significant unmet patient need- U.S. FDA Orphan Drug Designation (ODD) follows receipt of ODD for zoci in pulmonary NECs
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 11:27 AM
- Checked
- Aug 3, 2026, 11:27 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Zai Lab shares are trading higher after the company reported better-than-expected Q2 sales results.
Read original at benzinga8-K filing — Zai Lab Ltd (ZLAB)
Filed: 2026-08-06 AccNo: 0001628280-26-053791 Size: 395 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarZai Lab Q2 EPS $(0.46) Misses $(0.06) Estimate, Sales $105.751M Beat $105.323M Estimate
Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.06) by 666.67 percent. This is a 24.32 percent decrease over losses of $(0.37) per share from the
Read original at benzinga